Abstract
Extrafine beclometasone dipropionate/formoterol 100/6 and 200/6 μg fixed-dose combination (FDC) is available in the EU as a pressurized metered-dose inhaler (Fostair®, Foster®, Formodual®, Innovair®, Inuvair®, Inuxair®, Combair®) and a dry-powder inhaler (Fostair NEXThaler®, Foster NEXThaler®, Formodual NEXThaler®, Innovair NEXThaler®, Inuvair NEXThaler®). It is an effective, convenient and well-tolerated option for maintenance, or maintenance and reliever therapy in patients with asthma, as well as for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD). Extrafine beclometasone/formoterol is generally well tolerated, improves lung function and asthma control and reduces COPD exacerbations in these patients in clinical studies. It is generally more effective than beclometasone and formoterol monotherapies in clinical studies and generally provided better asthma control, reduced the use of rescue medication and improved health-related quality of life compared with large-particle FDCs in real-world studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
